Bessemer Group
JANX icon

Bessemer Group’s Janux Therapeutics JANX Stock Holding History

Bessemer Group’s Portfolio JANX Stock Details JANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$0 Buy
+28
New +$406 ﹤0.01% 2586

Other funds holding JANX

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

Bessemer Group's JANX Position: Q2 2026 in Review

Bessemer Group opened a new position in Janux Therapeutics (JANX) in Q2 2026: 28 shares worth $0. The stake represents ﹤0.01% of the portfolio and ranks #2586 among its holdings.

198 funds tracked by Wall St. Rank hold JANX as of Q2 2026.

  • Bessemer Group held 28 shares of Janux Therapeutics worth $0 as of Q2 2026.
  • Janux Therapeutics was a new Bessemer Group position in Q2 2026.
  • Janux Therapeutics made up ﹤0.01% of Bessemer Group's portfolio in Q2 2026, its #2586 holding.
  • 198 funds tracked by Wall St. Rank held Janux Therapeutics as of Q2 2026.

Based on Bessemer Group's 13F filing for Q2 2026, filed 12 Aug 2026.